Barclays
VBIV

Barclays’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Barclays’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,278
Closed -$29.8K – 5208
2023
Q1 		$29.8K Buy
3,278
+1,552
+90% +$22K ﹤0.01% 4573
2022
Q4 		$20.2K Buy
1,726
+1,453
+532% +$25.6K ﹤0.01% 4809
2022
Q3 		$6K Sell
273
-50
-15% -$1.35K ﹤0.01% 4480
2022
Q2 		$8K Buy
+323
New +$11K ﹤0.01% 4704
2021
Q3 		– Sell
-2,839
Closed -$285K – 5077
2021
Q2 		$285K Sell
2,839
-2,251
-44% -$219K ﹤0.01% 3385
2021
Q1 		$475K Buy
5,090
+2,924
+135% +$296K ﹤0.01% 3206
2020
Q4 		$179K Buy
+2,166
New +$185K ﹤0.01% 3824
2020
Q1 		– Sell
-2
Closed – – 6548
2019
Q4 		$0 Sell
2
-1,377
-100% -$30.2K ﹤0.01% 6917
2019
Q3 		$19K Buy
+1,379
New +$28.9K ﹤0.01% 6227
2018
Q2 		– Sell
-223
Closed -$23K – 7365
2018
Q1 		$23K Sell
223
-545
-71% -$65K ﹤0.01% 6378
2017
Q4 		$98K Buy
768
+751
+4,418% +$92.3K ﹤0.01% 5264
2017
Q3 		$2K Sell
17
-174
-91% -$20.9K ﹤0.01% 6701
2017
Q2 		$25K Buy
+191
New +$25.8K ﹤0.01% 5690

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's VBIV Position: Q2 2023 in Review

Barclays sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 3,278 shares — an estimated $29.8K sold.

Barclays first reported a position in VBIV in Q2 2017 and held it in 13 quarters. The position peaked at $475K in Q1 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • Barclays reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 3,278 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $29.8K.
  • Barclays first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2017 and held it in 13 quarters.
  • Barclays's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $475K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.